Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
19.79
+0.29 (1.49%)
At close: Jul 21, 2026, 4:00 PM EDT
19.80
+0.01 (0.06%)
After-hours: Jul 21, 2026, 4:25 PM EDT
Capricor Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Capricor Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $53.6. The average 1-year stock price forecast is 170.84% higher than the current stock price, while the lowest is $38 (+92.02%) and the highest is $63 (+218.34%).
Price Target: $53.6 (+170.84%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Capricor Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 7 | 7 | 8 | 8 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $62 | Buy | Maintains | $62 | +213.29% | Jul 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $60 | Buy | Reiterates | $60 | +203.18% | Jun 29, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $54 | Buy | Reiterates | $54 | +172.87% | Jun 18, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $38 | Buy | Reiterates | $38 | +92.02% | May 29, 2026 |
| Alliance Global Partners | Alliance Global Partners | Buy Reiterates $51 | Buy | Reiterates | $51 | +157.71% | May 14, 2026 |
Financial Forecast
Revenue This Year
118.08M
Revenue Next Year
122.34M
from 118.08M
Increased by 3.61%
EPS This Year
-0.22
from -2.26
EPS Next Year
-0.64
from -0.22
EPS and Forward PE are based on non-GAAP adjusted numbers.